These findings indicated that differently from the administration of Cox2 inhibitors for the treatment of LAM, targeting Glrx might exert better anti‐tumour effects through multiple pathways rather than only regulating Cox2 expression. Here, PTGS2 is linked to lymphangioleiomyomatosis.